Omadacycline on community-acquired infections: A systematic review and single-arm meta-analysis

Abstract

Introduction. Community-acquired infections pose a significant burden on healthcare systems and are caused by a variety of pathogens with different severities. Increasing microbial resistance complicates treatment, highlighting the need for new therapies. Omadacycline, a novel antibiotic, has broad-spectrum activity against both Gram-positive and Gram-negative pathogens, particularly those involved in community-acquired infections.
Objective. To evaluate omadacycline’s efficacy and safety for treating community-acquired infections.
Materials and methods. We searched PubMed, Embase, and Cochrane for randomized and non-randomized studies on Omadacycline for community-acquired infections, with no time restrictions. Primary outcomes were clinical success at the end of treatment (EOT) and post-treatment evaluation (PTE). Secondary outcomes included the risk of adverse events (AEs). Statistical analysis was performed using R software.
Results. We analyzed data from 10 studies involving 1666 patients, addressing infections such as pneumonia, wound infections, cellulitis, major abscesses, lower extremity ulcers, erysipelas, cystitis, and bone/joint infections. The analysis showed a 90% [1133 patients; 95% CI 88% to 91%] clinical success rate at EOT and an 84% [1288 patients; 95% CI 82% to 86%] success rate at PTE. Adverse events occurred in 45% [1210 patients; 95% CI 32% to 59%], with 18% [164 patients; 95% CI 13% to 24%] experiencing gastrointestinal issues. The mortality rate was 0% [13 patients; 95% CI 0% to 1%].
Conclusions. Omadacycline achieved 90% clinical success at EOT and 84% at PTE, with a 45% rate of adverse events and no mortality. These results suggest that Omadacycline is a promising option for treating community-acquired infections.